IRIS UniCatt

Lucchini, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.619
EU - Europa 2.473
AS - Asia 2.300
SA - Sud America 521
Continente sconosciuto - Info sul continente non disponibili 129
AF - Africa 96
OC - Oceania 10
Totale 9.148
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.524
SG - Singapore 1.118
DE - Germania 888
CN - Cina 482
BR - Brasile 420
IT - Italia 414
SE - Svezia 360
VN - Vietnam 189
FR - Francia 180
FI - Finlandia 121
GB - Regno Unito 121
IE - Irlanda 103
ID - Indonesia 81
IN - India 76
JP - Giappone 67
BD - Bangladesh 53
UA - Ucraina 53
RU - Federazione Russa 52
HK - Hong Kong 48
CA - Canada 44
IQ - Iraq 34
PL - Polonia 31
AR - Argentina 30
NL - Olanda 30
ZA - Sudafrica 29
CI - Costa d'Avorio 27
KR - Corea 26
TR - Turchia 23
AT - Austria 20
MX - Messico 20
EC - Ecuador 18
CO - Colombia 17
BE - Belgio 15
PK - Pakistan 15
ES - Italia 13
SA - Arabia Saudita 12
VE - Venezuela 11
JM - Giamaica 10
MA - Marocco 9
TN - Tunisia 9
JO - Giordania 8
CH - Svizzera 7
KE - Kenya 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
CL - Cile 6
PY - Paraguay 6
TH - Thailandia 6
BO - Bolivia 5
IL - Israele 5
IR - Iran 5
LT - Lituania 5
RS - Serbia 5
UZ - Uzbekistan 5
BY - Bielorussia 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
MY - Malesia 4
NI - Nicaragua 4
NO - Norvegia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PS - Palestinian Territory 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
UY - Uruguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BH - Bahrain 3
CU - Cuba 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
GR - Grecia 3
HU - Ungheria 3
LY - Libia 3
MD - Moldavia 3
PE - Perù 3
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
EE - Estonia 2
ET - Etiopia 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
MK - Macedonia 2
MM - Myanmar 2
MT - Malta 2
OM - Oman 2
AM - Armenia 1
BG - Bulgaria 1
BS - Bahamas 1
CG - Congo 1
CY - Cipro 1
EG - Egitto 1
Totale 9.008
Salva come PNG Salva come JPEG
Città #
Singapore 651
Chandler 419
San Jose 390
Frankfurt am Main 359
Ashburn 355
Munich 134
Beijing 127
New York 109
Dublin 103
Rome 95
Los Angeles 91
Helsinki 73
Jakarta 68
Ho Chi Minh City 67
Lauterbourg 67
Tokyo 62
Chicago 61
Hefei 58
San Mateo 56
Boston 47
Hanoi 47
São Paulo 43
Hong Kong 41
Wilmington 39
Princeton 36
Redmond 35
Milan 33
Atlanta 32
Dallas 31
Nürnberg 31
Moscow 29
Buffalo 28
Abidjan 27
Santa Clara 27
The Dalles 26
Ann Arbor 25
Jacksonville 24
Nanjing 23
Seoul 23
Warsaw 22
Seattle 21
Brooklyn 20
London 20
Salt Lake City 20
Turku 20
Houston 19
Johannesburg 19
Cattolica 18
Kent 17
North Bergen 17
Nuremberg 17
Tukwila 17
Rio de Janeiro 16
Fairfield 15
Marseille 15
Baghdad 14
Council Bluffs 14
Orem 14
Paris 14
Phoenix 14
Bremen 13
Pune 13
Boardman 12
Chennai 12
Montreal 12
Woodbridge 12
Denver 11
Lappeenranta 11
Shanghai 11
St Louis 11
Düsseldorf 10
Las Vegas 10
Lawrence 10
Norwalk 10
Poplar 10
Amsterdam 9
Bexley 9
Brussels 9
Guangzhou 9
Washington 9
Amman 8
Ankara 8
Belo Horizonte 8
Dearborn 8
Falkenstein 8
Kingston 8
Memphis 8
Mexico City 8
Toronto 8
Vienna 8
Campinas 7
City of London 7
Columbus 7
Florence 7
Haiphong 7
Hyderabad 7
Naples 7
Pittsburgh 7
Portsmouth 7
Redwood City 7
Totale 4.718
Salva come PNG Salva come JPEG
Nome #
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis 324
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 307
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 300
Upper body involvement in GNE myopathy assessed by muscle imaging 269
Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations 257
Novel missense variants associated with GNE myopathy 249
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 245
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 182
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 169
Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis 166
Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience 162
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 160
A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis 160
TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis 158
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 154
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 153
Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review 151
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 149
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis 149
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 145
Novel SEC61G-EGFR fusion gene in pediatric ependymomas discovered by clonal expansion of stem cells in absence of exogenous mitogens 142
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy 142
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of myasthenia-myositis association from a large cohort of patients 132
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 129
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 128
Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis. 126
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 126
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 123
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 123
Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments 123
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 122
Oculopharyngeal muscular dystrophy: Clinical and neurophysiological features 121
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 121
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 120
A unique case of multiphasic ADEM or what else? 118
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 118
Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis 117
Clinical, Histopathologic, and Genetic Features of Patients With Myofibrillary and Distal Myopathies 116
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 116
Ixekizumab exposure associated with myelitis: A case report and a literature review 116
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 111
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 110
Fingolimod vs dimethyl fumarate in multiple sclerosis 106
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 106
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 103
Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study 100
COVID-19 presenting as a non-arteritic anterior ischemic optic neuropathy 99
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 96
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 96
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study 93
Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review 90
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 88
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy 87
Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase 86
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 85
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 85
Tumefactive Demyelinating Lesion Around a Developmental Venous Anomaly: A Rare Association 83
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 81
Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis 81
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 80
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 79
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 79
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 78
Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations 78
Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis 77
Shift of multiple sclerosis onset towards older age 77
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 74
Signs and symptoms of COVID-19 in patients with multiple sclerosis 74
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 40
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study 38
Muscle Imaging in Inclusion Body Myositis: Refinement of MRI Criteria and Insights Into Upper Body Involvement 26
Childhood trauma and treatment compliance in people with multiple sclerosis: The mediating role of physician-patient rapport 23
Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications 22
Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients 10
Dynamics of Myelin-Specific T-Cell Repertoires Mirror Disease Activity and Central Nervous System Trafficking in Multiple Sclerosis 10
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 9
Totale 9.148
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.185
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.185
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022418 0 0 8 63 8 15 5 73 32 27 80 107
2022/20231.116 132 141 78 167 71 137 58 104 137 25 46 20
2023/2024638 25 148 26 38 18 109 44 50 11 21 66 82
2024/20251.451 30 37 110 66 64 91 99 73 193 126 347 215
2025/20263.755 481 86 211 390 624 499 574 176 252 220 136 106
2026/2027891 155 633 103 0 0 0 0 0 0 0 0 0
Totale 9.148